Predict your next investment

HEALTHCARE | Biotechnology
noviratherapeutics.com

See what CB Insights has to offer

Founded Year

2009

Stage

Acquired | Acquired

Total Raised

$40.05M

About Novira Therapeutics

Novira Therapeutics is an antiviral drug discovery company that is focused on the discovery of first-in-class antiviral therapeutics for the treatment of chronic HBV and HIV infections, two global diseases with high levels of unmet need. Novira's oral drugs target the capsid of the virus, and offer a promising treatment option both as monotherapy and in combination with current standards of care. The company's antivirals potentially address limitations in treating chronic HBV infection, a disease for which the only class of oral drugs available, polymerase inhibitors, are rarely curative and often require lifelong treatment, as well as in chronic HIV infection, a disease for which the continued ability of the virus to mutate inevitably leads to drug-resistant viral strains. Each of these limitations to the standard of care can potentially be addressed by capsid inhibitors which feature a new mechanism of action.

Novira Therapeutics Headquarter Location

3805 Old Easton Road

Doylestown, Pennsylvania, 18902,

United States

267-337-6913

Latest Novira Therapeutics News

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Nov 13, 2019

$250 | Single User $500 | Site License $750 | Global License [Lowest Price Guaranteed: $250] Summary Johnson & Johnson (J&J) researches and develops, and manufactures and sells a range of pharmaceutical products, medical devices and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in baby care, oral care, beauty, over-the-counter (OTC) pharmaceutical, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopedic, surgery, diabetes care and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US. Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company's operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Table of Contents Jun 22, 2018: Johnson & Johnson Appoints Senior Leaders to Executive Committee 572 Mar 20, 2018: Dominic J. Caruso to Retire as Chief Financial Officer of Johnson & Johnson 573 May 15, 2017: Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson 574 Legal and Regulatory 575 Apr 03, 2018: JNJ DEADLINE NOTICE: Rosen Law Firm Reminds Johnson & Johnson Investors of Important April 9, 2018 Deadline in Class Action - JNJ 575 Sep 19, 2017: GHJP Closes Two-Year FOIA Case Against Drug Manufacturer 576 May 31, 2017: Attorney General DeWine Files Lawsuit Against Opioid Manufacturers for Fraudulent Marketing; Fueling Opioid Epidemic 577 Jan 05, 2017: Missouri Court Denies J&J Request to Delay Talc-Related Cancer Trials 578 Government and Public Interest 579 Jun 05, 2018: Johnson & Johnson Announces Progress Toward Health for Humanity Goals 579 Dec 05, 2017: Bioethics International Releases the "Good Pharma Scorecard" in BMJ Open, Ranking the Top 20 Largest Pharmaceutical Companies on Clinical Trial Transparency 580 Nov 30, 2017: New HIV Prevention Trials Hold Promise for New Prevention Options for Women 581 Product News 582 12/11/2017: Kura Oncology Identifies Potential Biomarkers of Activity for Lead Candidate Tipifarnib in Bone Marrow Cancers 582 09/29/2017: Johnson & Johnson Advances Investigational Ebola Prime-boost Vaccine Regimen with New Partnership 584 08/02/2017: FDA Advisory Committee Does Not Recommend Approval Of Sirukumab For The Treatment Of Moderately To Severely Active Rheumatoid Arthritis 586 07/18/2018: Update on Janssens BACE inhibitor program regarding the dominantly inherited al List Of Tables List of Tables Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 21 Johnson & Johnson, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 22 Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 23 Johnson & Johnson, Deals By Therapy Area, 2012 to YTD 2018 24 Johnson & Johnson, Medical Devices Deals, 2012 to YTD 2018 26 Johnson & Johnson, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 28 Janssen Pharma Acquires CERC-501 from Cerecor 62 Cilag Acquires Rights to Rhinocort Aqua Outside the US from Astrazeneca 63 Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For US2 Million 64 Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 66 Twentyeight-Seven Therapeutics Raises USD65 Million in Series A Venture Financing 67 PhaseBio Pharma Raises USD34 Million in Series D Venture Financing 69 ApoGen Biotech Raises Additional USD4 Million in Series A Financing 71 Magnolia Neurosciences Raises USD31 Million in Series A Venture Financing 73 Evolve BioSystems Raises USD40 Million in Series C Financing 75 Syndesi Therapeutics Raises USD21 Million in Series A Financing 77 On Target Labs Raises USD40 Million in Series B Financing 79 BeneVir Biopharm Raises USD2 Million in Venture Financing 80 Fusion Pharma Raises Additional USD17 Million in Series A Financing 81 XW Labs Raises USD17.5 Million in Series B Financing 83 Rodeo Therapeutics Raises USD5.9 Million in Series A Financing 84 E-scape Bio Raises Additional USD8 Million in Series A Financing 86 DayTwo Secures USD12 Million in Series A Funding 88 DayTwo Raises USD12 Million in Series A Financing 89 Aragon Pharmaceuticals Raises USD22 Million in Series B Round of Financing 90 Biomx Raises USD24 Million in Series A Venture Financing 91 Pulmocide Raises USD30.4 Million in Series B Financing 93 Fusion Pharma Raises USD19 Million in Series A Financing 95 SuperX Raises USD11 Million in Series A Financing 96 Caelus Health Raises USD2.7 Million in Series A Financing 97 ApoGen Biotech Raises USD7 Million in Series A Financing 98 ReVision Optics Raises USD32 Million in Venture Financing 100 Blackthorn Therapeutics Raises USD40 Million in Series A Financing 102 BeneVir Biopharm Raises USD3 Million in Venture Financing 104 V-Wave Raises USD28 Million in Venture Financing 105 Lodo Therapeutics Raises USD17 Million in Series A Financing 106 Aelix Therapeutics Raises USD12.7 Million in Series A Financing 108 Petra Pharma Raises USD48 Million in Series A Financing 109 Protekt Therapeutics Raises More Than USD2 Million in Financing 111 Navitor Pharma Raises USD33 Million in Series B Financing 112 First Aid Shot Therapy Raises USD24 Million in Series C Financing 114 PrEP Biopharm Raises USD32.4 Million in Series A Financing Round 115 Asceneuron Raises USD30.6 Million in Series A Financing 116 Merus Raises USD46.4 Million in First Tranche of Series C Financing 118 E-scape Bio Raises USD55 Million in Series A Financing 120 Alligator Bioscience to Raise Funds through Venture Financing 122 Protagonist Therapeutics Raises USD40 Million in Series C Financing 123 PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 125 Protagonist Therapeutics Raises Additional Funds through Second Tranche of Series B Venture Financing 127 BeneVir Biopharm Raises Funds through Series A Financing 128 Tetra Discovery Raises Funds through Venture Financing 129 XW Labs Raises USD5.5 Million in Series A Financing 130 Inviata Raises USD6.5 Million in Venture Financing 131 ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 132 Ascelegen Therapeutics Raises Funds through Venture Financing 133 Padlock Therapeutics Raises Funds through Series A Financing 134 Navitor Pharma Raises USD24 Million in Series A Financing 135 Aduro BioTech Raises USD55 Million in Series C Financing 137 Rodin Therapeutics Raises USD13 Million in Series A Venture Financing 138 Assembly Pharma Raises Funds Through Seed Financing 139 Alios BioPharma Raises US Million In Series B Venture Financing 140 Covagen Raises US.3 Million In Series B Financing 141 Novira Therapeutics Raises US Million In Series A Financing 143 SutroVax Raises Funds Through Initial Financing Round 145 TopiVert Raises USD28 Million in Venture Financing 146 TopiVert Raises US.4 Million In Venture Financing 148 Pulmocide Raises US.4 Million In Series A Financing 150 Biocartis Raises US.5 Million In Series E Financing 152 Merus Raises US Million In Extended Series B Financing 154 Rodin Therapeutics Raises Funds Through Seed Financing 156 Vedanta Biosciences Raises Funds Through Venture Financing 157 XO1 Raises USD11 Million in Venture Financing 158 X01 Raises US Million In Series A Financing 159 Catalyst Biosciences Secures USD5.07 Million in Venture Funding 160 Novira Therapeutics Secures USD25 Million in Venture Funding 162 Aquinox Pharma Raises US Million In Series C Financing 163 Biocartis Raises US.7 Million In Series D Financing 164 Genocea Biosciences Raises US Million In Series C Financing 166 Aragon Pharma Raises US Million In Series D Financing 168 PhaseBio Pharma Raises Additional US Million In The Third Tranche Of Series B Financing Round 169 Celladon Raises Additional US Million In Series D Financing 171 Direct Flow Medical Secures USD0.28 Million in Venture Funding 173 Coherex Medical Secures USD16.5 Million in Venture Funding 174 Aragon Pharma Raises US Million In Series C Financing 175 Johnson & Johnson Innovation - JJDC to Invest USD75 Million in Arrowhead Pharma 176 Platinum Equity Acquires LifeScan from Johnson & Johnson for USD2.1 Billion 178 Johnson & Johnson Innovation-JJDC Invests USD4.7 Million in TRACON Pharma 179 Janssen Amends Licensing Agreement with Gilead for STR 180 Janssen Enters Into Licensing Agreement With PATH For Rilpivirine 181 Janssen Pharma to Enter into Research and Option Agreement with Arrowhead Pharma 182 Janssen Vaccines & Prevention, CEPI and Jenner Institute Enter into Partnership 183 RespireRx Pharma Enters into Agreement Noramco 184 Merck Enters into Co-Development Agreement with Xian-Janssen Pharma 185 GenomeDx Biosciences Enters into Agreement with Janssen Pharma 186 Noramco and SPI Pharma Enter into Agreement 187 Bristol-Myers Squibb Enters into Partnership with Janssen Pharma 188 Janssen Pharma to Enter into Agreement with Pharmstandard 189 Aldeyra Therapeutics Enters into Research Agreement with Janssen Research & Development 190 Janssen Biotech Enters into Co-Development Agreement with Theravance Biopharma Ireland 191 Janssen Biotech Enters into Research Agreement with Koch Institute for Integrative Cancer Research 192 Johnson & Johnson Innovation and Janssen Biotech Enter into Partnership with Monash University 193 Janssen Pharma Enters into Research Partnership with Beacon Discovery 194 Johnson & Johnson Innovation, Johnson & Johnson Consumer Enter into Partnership with Dermala 195 Johnson & Johnson Innovation and Janssen Pharma Enter into Research Partnership with University of Pennsylvania 196 Johnson & Johnson Innovation, Johnson & Johnson Consumer and Janssen Research & Development Enter into Research Partnership with Holobiome 197 Johnson & Johnson Innovation, Janssen Research & Development Enter into Partnership with Taiwan Industrial Technology Research Institute 198 Beacon Discovery Enters into Co-Development Agreement with Janssen Pharma 199 Taiho Pharma Enters into Co-Marketing Agreement with Janssen Pharma 200 Genomic Health Enters into Research Agreement with Janssen Pharma 201 BioMed X Enters into Agreement with Janssen Research & Development 202 Cerveau Technologies Enters into Agreement with Janssen Pharma 203 Janssen Research & Development Enters into Agreement with U.S. Department of Health 204 Janssen Pharmaceutica Enters into Distribution Agreement with Mundipharma Medical 205 Johnson & Johnson to Enter into Agreement with Institute of Microbial Technology 206 Proteros biostructures Enters into Research Agreement with Janssen Biotech 207 University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 208 Idorsia and Janssen Biotech to Enter into option Agreement 209 Monash University Enters into Research Agreement with Janssen Biotech 210 Phagelux Enters into Agreement with Johnson & Johnson Consumer 211 Janssen Research & Development Enters into Agreement with Castleman Disease Collaborative Network 212 PeptiDream Enters into Agreement with Janssen Pharma 213 Janssen Pharma Enters into Partnership with Premier 214 Renova Therapeutics Enters into Agreement with Janssen Pharma 215 Mitsubishi Tanabe Pharma Expands Co-Promotion Agreement with Janssen Pharma 216 Janssen Research & Development Enters into Research Agreement with Weizmann Institute of Science 217 Janssen Research & Development Enters into Agreement with DayTwo and the Weizmann Institute of Science 218 Janssen Research & Development Enters into Agreement with ChemDiv 219 DePuy Synthes Enters into Co-Promotional Agreement with Pacira Pharma for EXPAREL 220 Enamine Expands Agreement with Actelion 221 Karolinska Institutet Partners with Johnson & Johnson Companies 222 Janssen Biotech Enters into Partnership with Bristol-Myers 223 Janssen Vaccines & Prevention Enters into Research and Licensing Option Agreement with Synthetic Genomics 224 Janssen Biotech Partners with Weill Cornell Medicine to Develop Prostate Cancer Therapies 225 Janssen Pharma Enters into Partnership with Bird Rock Bio 226 Janssen Pharma Enters into Agreement with Medicines for Malaria Venture 227 Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 228 Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 229 HitGen Enters into Agreement with Janssen Biotech 230 Innovative Targeting Solutions Enters into Research Agreement with Janssen Biotech 231 Xycrobe Therapeutics Enters into Research Agreement with Johnson & Johnson Consumer 232 Philogen Enters Into Collaboration Agreement With Janssen Biotech 233 Diamyd Medical Enter into Partnership with Janssen R&D, JDRF and UAB 234 Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 235 Amyris Enters into Research Agreement with Janssen Biotech 236 Janssen Research & Development Enters into Agreement with Genentech 237 Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 238 DiamiR Enters into Research Agreement with Janssen Pharma 239 Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 240 Janssen Biotech Enters into Agreement with HUB foundation 241 Janssen Pharma Enters into Agreement with University of Pennsylvania 242 Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 243 Johnson & Johnson Consumer Enters into Agreement with ProdermIQ 244 Johnson & Johnson Consumer Enters into Research Agreement with University of Pennsylvania 245 Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 246 ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 247 Janssen Pharma Enters into Agreement with University of California, San Diego 248 Enterome Bioscience Enters into Research Agreement with Janssen Biotech 249 Johnson & Johnson Consumer Enters into Agreement with BioMed X 250 Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 251 Janssen Research & Development Enters into Research Agreement with Skaggs School of Pharmacy and Pharmaceutical Sciences 252 Janssen Biotech Enters into Agreement with Eureka Therapeutics 253 Intrexon Enters into Research Agreement with Janssen Pharma 254 Cypralis Enters into Research Agreement with Janssen Pharma 255 Janssen Pharma Enters into Agreement with Foundation for Innovative New Diagnostics 256 Bioaster, Cancer Research Center of Lyon and Janssen-Cilag Enter into Agreement 257 SynAging Extends Agreement with Actelion Pharma 258 ViroGin Biotech Enters into With Johnson & Johnson Innovation and Janssen Biotech 259 Nuevolution Enters into Discovery Agreement with Janssen Biotech 260 enGene Enters into Agreement with Janssen Biotech 261 OICR and Novera Therapeutics Enter into Co-Development Agreement with Janssen Biotech 262 BlinkBio Enters into Discovery Agreement with Janssen Pharma 263 UbiVac Enters into Agreement with Janssen Biotech 264 Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 265 Nextera Enters into Research Agreement with Janssen Biotech 266 Handok Enters into Agreement with Actelion Pharmaceuticals 267 Actelion Forms Joint Venture with Max Planck Society 268 Johnson & Johnson Enters into Agreement with University of the Witwatersrand 269 Janssen Cilag Enters into Agreement with UniQuest 270 Johnson & Johnson Innovation Enters into Research Agreement with Washington University 271 Janssen Biotech Enters into Research Agreement with Emulate 272 Johnson & Johnson Innovation Partners with Lead Discovery Center 273 NeurOp Enters into Research Agreement with Janssen Pharma 274 AC Immune Enters into Research Agreement with Janssen Pharma 275 X-Chem Expands Agreement with Janssen Biotech 276 Vectura Enters into Development and License Agreement with Janssen Biotech 277 Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 278 Sevion Therapeutics Enters into Discovery Agreement with CNA Development 279 Atreca Enters into Research Agreement with Janssen Biotech 280 Vaccinex Enters into Research Agreement with Janssen Research & Development 281 Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 282 Weill Cornell Medical College Enters into Co-Development Agreement with Janssen Biotech and Johnson & Johnson Innovation 283 Johnson & Johnson Enters into Co-Development Agreement with University of Manchester 284 ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland 285 Alector Enters Into Research Agreement With Janssen Pharma 286 University of Texas MD Anderson Cancer Center Enters Into Co-Development Agreement With Johnson & Johnson Innovation And Janssen Biotech 287 Nodality Enters Into Research Agreement With Johnson & Johnson Innovation 288 Scholar Rock Enters Into Research Collaboration With Johnson & Johnson Innovation And Janssen Biotech 289 Intrexon Enters Into R&D Agreement With Johnson & Johnson Innovation For Skin And Hair Products 290 Capricor Enters Into Co-Development Agreement With Janssen For Cell Therapy For Cardiovascular Applications 291 Evotec Enters Into Co-Development Agreement With Johnson & Johnson 292 ZoBio Enters Into Drug Discovery Agreement With Actelion Pharma For Fragment Ligands 293 AstraZeneca Enters Into Co-Promotion Agreement With Janssen For Abiraterone Acetate 294 Joslin Diabetes Center Enters Into R&D Agreement With Johnson & Johnson For Diabetes Management 295 DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 296 Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 297 ex scientia Enters into Agreement with Janssen Research & Development 299 Mellitech Enters into Agreement with Janssen Pharma 300 Second Genome Enters Into Agreement With Janssen Biotech For Microbiome Drug Discovery 301 Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 302 Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 303 Araxes Pharma Enters Into Drug Discovery Agreement With Janssen Biotech For Cancer 304 Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 305 Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 306 Open Monoclonal Expands Agreement with CNA Development 307 Beactica Enters Into Research Agreement With Janssen Research & Development 308 Janssen-Cilag Enters Into Research Agreement With University of Melbourne 309 Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands 310 Artes Biotechnology Enters Into Co-Development Agreement With Crucell 311 Selventa Enters Into Co-Development Agreement With Janssen Research & Development 312 Johnson & Johnson Enters Into Co-Development Agreement With University of Queensland 313 Dendright Enters Into Research Agreement With Janssen-Cilag 314 FORMA Therapeutics Enters Into Co-Development Agreement With Janssen Biotech 315 Janssen Pharma to Enter into Licensing Agreement with Arrowhead Pharma 316 Immune Biosolutions Enters into Licensing Agreement with Janssen Biotech 318 Macleods Pharma May Enter into Licensing Agreement with Johnson & Johnson 319 Janssen Biotech Enters into Licensing Agreement with Nuevolution 320 Janssen Biotech Enters into Licensing Agreement with Legend Biotech 321 Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 322 Janssen Biotech Enters into Licensing Agreement with Zymeworks 323 Provention Enters into Licensing Agreement with Janssen Pharma and Janssen Sciences Ireland 324 Janssen Biotech Enters into Licensing Agreement with Protagonist Therapeutics 325 Janssen Pharma Enters into Licensing Agreement with St Vincent’s Institute of Medical Research 327 Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 328 Pulmatrix Enters into Licensing Agreement with RespiVert 329 Janssen Biotech Enters into Licensing Agreement with Trianni 330 Janssen Biotech Enters into Licensing Agreement with Ablexis 331 Akebia Therapeutics Enters into Licensing Agreement with Janssen Pharma 332 Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 334 CPDC Enters into Licensing Agreement with Janssen Biotech for Centyrin 335 OCTIMET Oncology Enters into Licensing Agreement with Janssen Pharma 336 BenevolentAI Enters into Licensing Agreement with Janssen Pharma 337 Actelion Enters into Licensing Agreement with ReveraGen BioPharma 338 TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC694 339 TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC253 341 Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 343 GlaxoSmithKline Enters into Licensing Agreement with Janssen Sciences Ireland 344 Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 345 Janssen Biotech Exercises Option for Licensing Agreement with OSE Immunotherapeutics 346 Janssen Biotech Enters into Licensing Agreement with MacroGenics for MGD015 347 Janssen Biotech Enters into Licensing agreement with Tesaro 348 ViaCyte Enters into Licensing Agreement with Janssen Biotech 349 Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 350 Janssen Biotech Exercises Option for Licensing Agreement with Scholar Rock 351 Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 352 Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 353 Janssen Biotech Enters into Licensing Agreement with Alligator Bioscience for ADC-1013 354 Poseida Therapeutics Enters into Licensing Agreement with Janssen Biotech 355 Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 356 Poseida Therapeutics Enters into Licensing Agreement with Janssen 357 Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 358 GBC-Atrial Enters into Licensing Agreement with Actelion Pharma 359 Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 360 Infirst Healthcare Enters into Licensing Agreement with McNeil Consumer Pharma 361 Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 362 Applied Molecular Transport Enters into Licensing Agreement with Janssen Biotech 363 Vedanta Biosciences Enters into Licensing Agreement with Janssen Biotech 364 AC Immune Enters into Licensing Agreement with Janssen Pharma 365 Janssen Expands Licensing Agreement with Gilead 366 Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 367 Kura Oncology Amends Licensing Agreement with Janssen Pharma 369 Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 371 Modern Biosciences Enters into Licensing Agreement with Janssen Biotech 372 Transposagen BioPharma Enters into Licensing Agreement with Janssen Biotech 373 BeneVir Biopharm Enters into Licensing Agreement with New York University 374 AB-Biotics Enters into Licensing Agreement with Cilag 375 Bavarian Nordic Enters into Licensing Agreement with Crucell Holland 376 Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 377 Minerva Amends Licensing Agreement with Janssen Pharma for MIN-202 378 Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 380 Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 381 Janssen R&D Ireland Extends Licensing Agreement With International Partnership For Microbicides 382 Janssen Pharma Enters into Licensing Agreement with BiocerOX 384 Orion Enters Into Licensing Agreement With Janssen Pharma 385 CSL Enters Into Licensing Agreement With Janssen For CSL-362 386 Janssen Biotech Exercises Option For Licensing Agreement With Forma Therapeutics 388 Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 389 XO1 Enters into Licensing Agreement with Cambridge Enterprise 390 Amunix Expands Licensing Agreement With Janssen For XTEN Technology 391 Amunix Expands Licensing Agreement With Janssen Biotech For Proprietary XTEN Technology 392 GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 393 NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 394 Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 395 Phenex Pharma Enters Into Licensing Agreement With Janssen Biotech For Retinoid-Acid Receptor-Related Orphan Receptor Gamma t Program 397 Shionogi Enters Into Licensing Agreement With Janssen Pharma 398 Covagen Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 399 ImmuNext Enters Into Licensing Agreement With Janssen Biotech 401 Genmab Enters into Licensing Agreement with Janssen Biotech for Daratumumab 402 Depomed Enters Into Licensing Agreement With Janssen Pharma 404 Genmab Enters into Licensing Agreement with Janssen Biotech for DuoBody Technology 405 Genmab Expands Licensing Agreement With Janssen Biotech 406 Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 407 Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 409 Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 410 Phylogica Enters Into Licensing Agreement With Janssen Biotech For Phylomer Technology 411 Janssen Pharma Enters into Licensing Agreement with Arcturus Therapeutics 412 Janssen Biotech Exercises Option for Licensing Agreement with X-Chem 413 Dishman Pharma Enters into Licensing Agreement with Janssen Pharma 414 BRIM Biotechnology Enters into Licensing Agreement with Janssen Pharma 415 ViaCyte Enters into Option for Licensing Agreement with Janssen Research & Development 416 Covagen Expands Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 417 Amunix Exercises Option For Licensing Agreement With Janssen Biotech For XTEN Technology 419 Intravacc Enters into Licensing Agreement with Crucell Holland 420 Janssen Pharma Enters Into Licensing Agreement With Scripps Research Institute For Infectious Diseases 421 BioLife Solutions Enters Into Licensing Agreement With Janssen Research & Development For CryoStor 422 Janssen Pharma Enters Into Licensing Agreement With Pharmstandard For Bedaquiline, Anti-Tuberculosis Drug 423 NewVac Enters Into Licensing Agreement With Janssen For Quisinostat 424 Mucosis To Enter Into Licensing Agreement With Crucell For Mimopath Technology 425 Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 426 Kuros Biosurgery Enters Into Licensing Agreement With Synthes 428 Theratechnologies Enters Into Licensing Agreement With Actelion Pharma For Lipodystrophy Drug 429 Bavarian Nordic Raises USD32.5 Million in Private Placement of Shares 430 Actelion Spun Out its Drug Discovery and Early Clinical Pipeline Business 432 Achillion Pharma to Raise Funds through Secondary Offering of Shares 433 Alligator Bioscience Raises USD252.8 Million in IPO 435 Tesaro Raises USD50 Million in Private Placement of Shares 437 Achillion Pharma Raises USD225 Million in Private Placement of Shares 438 Minerva Neurosciences Raises USD31 Million in Private Placement of Shares 440 Kura Oncology Raises USD60 Million in Private Placement of Common Stock 442 MacroGenics Raises USD75 Million in Private Placement of Common Stock 444 Bavarian Nordic Raises USD43 Million in Private Placement of Shares 446 PhaseBio Pharma to Raise USD8.1 Million in Second Tranche of Private Placement of Convertible Notes 447 PhaseBio Pharma Raises USD14.7 Million in Private Placement of Convertible Notes 449 Johnson & Johnson Plans to Raise Funds through Public Offering of Notes 451 Johnson & Johnson Completes Public Offering Of Notes Due 2018 For US0 Million 452 Johnson & Johnson Completes Public Offering Of Notes Due 2016 For US0 Million 454 Johnson & Johnson Completes Public Offering Of Notes Due 2023 For US0 Million 456 Johnson & Johnson Completes Public Offering Of Notes Due 2033 For US0 Million 458 Johnson & Johnson Completes Public Offering Of Notes Due 2043 For US0 Million 460 Johnson & Johnson Completes Public Offering Of Notes Due 2016 For US0 Million 462 Eusa Pharma to Acquire Sylvant from Janssen Sciences Ireland for USD115 Million 464 Stada Arzneimittel Acquires Nizoral from Janssen Pharma 465 Kramer Labs Acquires Nizoral from Janssen Pharma 466 Alliance Pharma Acquires Nizoral from Janssen Pharma for USD79.5 Million 467 VIVUS Acquires Assets from Janssen Pharma for USD135 Million 468 Helsinn Healthcare to Acquire Rights of Valchlor/Ledaga from Actelion Pharma 469 Sinocare May Acquire Diabetes Care Business from Johnson & Johnson for up to USD4 Billion 470 HRA Pharma Acquires Compeed from Cilag 471 Trimb Healthcare Acquires OTC Products from Cilag and Janssen Pharma 472 Church & Dwight Acquires Anusol and Rectinol Business from Johnson & Johnson for USD130 Million 473 Piramal to Acquire Five Anesthesia and Pain Management Injectable Products from Janssen Pharma 474 Strides Arcolab to Acquire Seven Brands from Johnson & Johnson 476 Air Liquide Acquires Healthcare Antisepsis Solutions from Ethicon 477 Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 478 Vivus Acquires Topiramate Related Patents from Janssen Pharma 480 PaxVax Acquires Vivotif from Crucell 481 Reckitt Benckiser To Acquire K-Y Lubricants Brand From McNEIL-PPC 482 Bertin Pharma Acquires R&D Facility from Johnson & Johnson Sante Beaute France 483 Abbott Labs And Organon BioSciences Plan To Acquire Certain Pharma Assets From Johnson & Johnson 484 Chattem Completes Acquisition Of Rolaids From McNEIL-PPC 486 Recordati Acquires Dentosan Line Of Oral Care Products From Cilag 487 Furiex Pharma Acquires Priligy From Janssen Pharmaceutica And Alza 488 Recordati Acquires Six Over The Counter Products From Cilag And McNeil 489 Forest Labs Acquires Patents And Intellectual Property For Bystolic From Janssen Pharma For US7 Million 490 Shire Acquires US Rights Of Resolor From Janssen Pharmaceutica 491 Janssen Biotech Acquires 76% stake in BeneVir Biopharm 493 Johnson & Johnson Acquires Actelion for USD30 Billion 494 Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 496 Ethicon Acquires Torax Medical 498 Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 499 Johnson & Johnson Consumer Acquires NeoStrata 501 DePuy Orthopaedics Acquires BioMedical Enterprises 502 Johnson & Johnson Sells its 5.1% Interest in Galapagos for USD95.7 Million 503 Johnson and Johnson May Sell Noramco 504 Johnson & Johnson Acquires Novira Therapeutics 505 Biosense Webster Acquires Coherex Medical 506 Actelion Plans to Acquire ZS Pharma 507 Actelion Rejects Acquisition Offer from Shire 508 Janssen Pharma Acquires XO1 509 Valneva Acquires Crucell Sweden for USD54 Million 510 Tetraphase Pharma May Sell Itself 511 Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion 513 Cilag Acquires Covagen 515 Actelion Completes Acquisition Of Ceptaris Therapeutics For US0 Million 518 Johnson & Johnson Completes Acquisition Of Aragon Pharma For USD1 Billion 521 Janssen Biotech Enters Into Option To Acquire Amphivena From Affirmed Therapeutics 523 Ipsen Acquires Syntaxin, Life Sciences Company, For USD206 Million 524 Johnson & Johnson Completes Acquisition Of Shanghai Elsker For Mother & Baby 526 Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 528 Janssen Biotech To Acquire Vascular Pharma, Diabetes Drug Developer 530 Janssen-Cilag Acquires CorImmun 531 Johnson & Johnson, Key Employees 534 Johnson & Johnson, Subsidiaries 535 in Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile List of Figures Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2 Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2 Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2 Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 21 Johnson & Johnson, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 22 Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 23 Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 24 Johnson & Johnson, Medical Devices Deals, 2012 to YTD 2018 26 Additional Details

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Novira Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Novira Therapeutics is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Novira Therapeutics Patents

Novira Therapeutics has filed 49 patents.

The 3 most popular patent topics include:

  • Diseases of liver
  • Infectious causes of cancer
  • Antivirals
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/15/2019

9/28/2021

Hepatology, Hepatotoxins, Prodrugs, Hepatitis, Diseases of liver

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/15/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/28/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Hepatology, Hepatotoxins, Prodrugs, Hepatitis, Diseases of liver

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.